Liquidia Corporation LQDA Generic Treprostinil — Program Expenses

Similar metrics at other companies

PRAXRelutrigine — Program-specific expenses

$12.85M+139%

RPRXPhase 2b, TEV-408 — Research and development funding expense

$14.3M—

ROIVBrepocitinib — Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)

$14.34M+9.7%

NUVLDiscovery Programs — Direct Expenses Related To Program

$2.8M+31.4%

BIIBTotal Operating Expenses

$2.1B-0.9%

NUVLNVL-330 — Direct Expenses Related To Program

$6.83M+72.3%

Questions, answered.

What is Liquidia Corporation's generic treprostinil — program expenses?

Liquidia Corporation (LQDA) reported generic treprostinil — program expenses of -$49K in Q1 2026.

How has Liquidia Corporation's generic treprostinil — program expenses changed year-over-year?

Liquidia Corporation's generic treprostinil — program expenses decreased by 132.5% year-over-year, from $151K to -$49K.

What is the long-term trend for Liquidia Corporation's generic treprostinil — program expenses?

Over 2 years (2023 to 2025), Liquidia Corporation's generic treprostinil — program expenses has grown at a 8.7% compound annual growth rate (CAGR), from $308K to $364K.

What does generic treprostinil — program expenses mean?

This metric represents the total direct costs and operating expenditures specifically allocated to the research, development, and commercialization activities for the generic treprostinil product line. It captures the financial resources deployed to advance this specific pharmaceutical program through its lifecycle, including manufacturing process development and regulatory efforts. Monitoring these expenses helps investors assess the capital intensity and investment commitment required to maintain the product's market position within the pulmonary hypertension portfolio.